Yi Zhang

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Ejection Fraction

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

British journal of haematology

Hematological oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ziyue Zhou, Nanfang Zhuo, Yile Zhou, Caihong Sun, Yiyi Yao, Liping Mao, Yi Zhang, Qing Hong, Peifeng Pan, Hong-Yan Tong, Jie Jin, Huafeng Wang
Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients. American journal of hematology 99 (7) (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Ziyue Zhou, Nanfang Zhuo, Yile Zhou, Caihong Sun, Yiyi Yao, Liping Mao, Yi Zhang, Qing Hong, Peifeng Pan, Hong-Yan Tong, Jie Jin, Huafeng Wang
Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients. American journal of hematology (2024)
Rong Wang, Yi Zhang, Jie Chang, Huafeng Wang, Yinjun Lou, Min Yang, Gaixiang Xu, Hongyan Tong, Wanzhuo Xie, De Zhou, Juying Wei, Wenyuan Mai, Xiu-Jin Ye, Haitao Meng, Jie Jin, Hong Hu Zhu
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis. Hematological oncology 42 (2) (2024)
Ziyue Zhou, Nanfang Zhuo, Yile Zhou, Caihong Sun, Yiyi Yao, Liping Mao, Yi Zhang, Qing Hong, Peifeng Pan, Hong-Yan Tong, Jie Jin, Huafeng Wang
Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients. American journal of hematology 99 (7) (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology (2024)
Shanshan Suo, Dandan Zhao, Fenglin Li, Yi Zhang, Sonia Rodriguez-Rodriguez, Le Xuan Truong Truong Nguyen, Lucy Y Ghoda, Nadia Carlesso, Guido Marcucci, Bin Zhang, Jie Jin
Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia. Blood (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Ziyue Zhou, Nanfang Zhuo, Yile Zhou, Caihong Sun, Yiyi Yao, Liping Mao, Yi Zhang, Qing Hong, Peifeng Pan, Hong-Yan Tong, Jie Jin, Huafeng Wang
Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients. American journal of hematology 99 (7) (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Yi Zhang, Hu Zhou, Ming-Hui Duan, Sujun Gao, Guang-Sheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huan-Ling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei Wang, Na Xu, Haiping Yang, Binhua Lu, Hewen Yin, Liqing Wu, Shanshan Suo, Qingwei Zhao, Zhijian Xiao, Jie Jin
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. American journal of hematology (2023)
Huafeng Wang, Yiyi Yao, Liping Mao, Yinjun Lou, Yanling Ren, Xingnong Ye, Min Yang, Liya Ma, Yi Zhang, Yile Zhou, Jiaying Wu, Xin Huang, Yungui Wang, Huan Xu, Shuanghong Zhu, Hong Hu Zhu, Jie Jin
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis. British journal of haematology (2023)
Yi Zhang, Qike Zhang, Qingchi Liu, Huibing Dang, Sujun Gao, Wei Wang, Hu Zhou, Yuqing Chen, Liangming Ma, Jishi Wang, Haiping Yang, Binhua Lu, Hewen Yin, Liqing Wu, Shanshan Suo, Qingwei Zhao, Hongyan Tong, Jie Jin
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. American journal of hematology (2023)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Wenjuan Yu, Jie Jin
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial. American journal of hematology 97 (12) (2022)
Huan-Ping Wang, Yile Zhou, Xin Huang, Yi Zhang, Jiejing Qian, Jianhu Li, Chenying Li, Xue-Ying Li, Yinjun Lou, Qiaoyun Zhu, Yujie Huang, Haitao Meng, Wenjuan Yu, Hong-Yan Tong, Jie Jin, Hong-Hu Zhu
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. British journal of haematology 193 (6) (2021)
Huan-Ping Wang, Yi-Le Zhou, Xin Huang, Yi Zhang, Jie-Jing Qian, Jian-Hu Li, Xue-Ying Li, Chen-Ying Li, Yin-Jun Lou, Wen-Yuan Mai, Hai-Tao Meng, Wen-Juan Yu, Hong-Yan Tong, Jie Jin, Hong Hu Zhu
CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. American journal of hematology 96 (3) (2020)